eHealthMe - Personalized health information & community eHealthMe - Personalized health information & community

Personalized health information & community

  Tools   Community
All drugs: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
All conditions: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Check symptoms       Ask question       Write review       Answered/ Unanswered       Reviews       WellConnected

From FDA reports: drug interactions between Duspatalin 200 Mg, Creon for a Male patient aged 44

This is a personalized study for a 44 year old male patient. The study is created by eHealthMe based on reports of 20 people who take the same drugs and have drug interactionsfrom FDA.

On Oct, 26, 2014: 20 people who reported to have interactions when taking Duspatalin 200 Mg, Creon are studied

Trend of Duspatalin 200 Mg, Creon's drug interactions, side effects, and effectiveness reports (3025101)

Information of the patient in this study:

Age: 44

Gender: male

Conditions: Biliary Dyskinesia, Pancreatic Enzymes Decreased

Drugs taking:
- Duspatalin 200 Mg: used for < 1 month
- Creon: used for < 1 month

Drug interactions have: Urticaria, Anaphylactic Shock

eHealthMe real world results:

Comparison with this patient's adverse outcomes among males aged 44 (±5):

InteractionNumber of reports
Urticaria (rash of round, red welts on the skin that itch intensely)4 (50.00%)
Anaphylactic Shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)4 (50.00%)

Most common interactions experienced by males aged 44 (±5) in the use of Duspatalin 200 Mg, Creon:

InteractionNumber of reports
Abdominal Pain8
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)8
Constipation6
Intestinal Obstruction6
Nausea (feeling of having an urge to vomit)6
Immunology Test4
Colonic Stenosis (abnormal narrowing of colon)4
Colonic Obstruction (obstruction in colon)4
Lymphadenitis Viral (viral infection of lymph node)4
Weight Decreased4

Most common interactions experienced by males aged 44 (±5) in long term use of Duspatalin 200 Mg, Creon:

None.

For people in general (regardless of gender or age):

Comparison with this patient's adverse outcomes:

InteractionNumber of reports
Urticaria (rash of round, red welts on the skin that itch intensely)4 (20.00%)
Anaphylactic Shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)4 (20.00%)

Most common interactions experienced by people in the use of Duspatalin 200 Mg, Creon:

InteractionNumber of reports
Pruritus (severe itching of the skin)12
Abdominal Pain10
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)9
Anxiety6
Aggression6
Panic Reaction6
Hallucination (an experience involving the perception of something not present)6
Screaming (a long loud piercing cry)6
Abnormal Behaviour6
Confusional State6

Most common interactions experienced by people in long term use of Duspatalin 200 Mg, Creon:

None.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

You can also:

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

   

About - Terms of service - Privacy policy - Press - Testimonials - Contact us

 
© 2014 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.